期刊文献+

高分辨熔解曲线法检测非小细胞肺癌p53基因的突变

High Resolution Melting Analysis for Detecting p53 Gene Mutations in Patients with Non-small Cell Lung Cancer
暂未订购
导出
摘要 背景与目的 p53基因与人类多种肿瘤相关,突变型具有致癌作用,主要分布在外显子5-8。本研究旨在建立高分辨熔解曲线(high resolution melting,HRM)检测非小细胞肺癌(non-small cell lung cancer,NSCLC)患者p53基因突变的方法,探讨p53基因突变的特点及其在NSCLC发生发展中的演变规律。方法采用HRM法检测264例NSCLC患者肿瘤组织和54例癌旁肺组织p53基因外显子5-8的突变,突变样品进一步使用PCR产物直接测序法分析确定突变类型;HRM法检测阳性而PCR产物直接测序法检测阴性的样品,进一步进行亚克隆测序证实。结果 54例对照未发现突变。264例肿瘤组织中,HRM法检出p53基因突变104例,102例得到PCR产物直接测序法证实,突变率为39.4%;95例为点突变,7例为碱基插入和缺失导致的移码突变。p53外显子5-8的突变率分别为11.7%、8%、12.5%和10.6%,差异无统计学意义(P=0.35)。p53基因突变与性别有关,与其它临床病理特征无关。结论 HRM法筛选p53基因突变样品,具有操作简便、快速、敏感、单管避免污染等优点,值得推广。p53基因的突变特点提示,p53基因突变是自发性突变,可能是DNA合成和修复过程中的随机错误所致。 Background and objective It has been proven that p53 gene was related to many human cancers. The mutations in p53 gene play an important role in carcinogensis and mostly happened in exon 5-8. The aim of this study is to establish a high resolution melting (HRM) assay to detect p53 mutations from patients with non-small cell lung cancer (NSCLC), to investigate the characteristics of p53 gene mutations, and to analyze the relationship between p53 mutations and evolution regularity of pathogenesis. Methods p53 mutations in exon 5-8 were detected by HRM assay on DNA insolated from 264 NSCLC samples derived from tumor tissues and 54 control samples from pericancerous pulmonary tissues. The mutation samples by the HRM assay were confirmed by sequencing technique. Samples which were positive by HRM but wild type by sequencing were further confirmed by sub-clone and sequencing. Results No mutation was found in 54 pericancerous pulmonary samples by HRM assay. 104 of the 264 tumor tissues demonstrated mutation curves by HRM assay, 102 samples were confirmed by sequencing, including 95 point mutations and 7 frame shift mutations by insertion or deletion. The mutation rate of p53 gene was 39.4%. The mutation rate from exon 5-8 were 11.7%, 8%, 12.5% and 10.6%, respectively and there was no statistically significant difference between them (P=0.35). p53 mutations were significantly more frequent in males than that in females, but not related to the other clinicopathologic characteristics. Conclusion The results indicate that HRM is a sensitive in-tube methodology to detect for mutations in clinical samples. The results suggest that the arising p53 mutations in NSCLC may be due to spontaneous error in DNA synthesis and repair.
出处 《中国肺癌杂志》 CAS 2011年第10期767-773,共7页 Chinese Journal of Lung Cancer
关键词 P53基因 突变 测序 p53 gene Mutation Sequence
  • 相关文献

参考文献9

  • 1Levesque AA, Eastman A. pS3-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis, 2007, 28(1): 13-20.
  • 2Olivier M, Hollstein Mj Hainaut P. TP53 mutations in human cancers: ori- gins, consequences, and clinical use. Cold Spring Harb Perspect Biol, 2010,2(1):a001008.
  • 3Michael K, Ahmed AA, Etemadmoghadam D, et al. High resolution melting for mutation scanning ofTP53 exons 5-8. BMC Cancer, 2007, 31: 168.
  • 4陈志红,郭爱林,安社娟,郑有为,马冬,苏健,谢至,黄迎,陈世良,吴一龙.HRM法检测结直肠癌组织KRAS基因密码子12和13点突变[J].中华检验医学杂志,2010,33(3):209-212. 被引量:8
  • 5Yamanoshita O, Kubota T, Hou J, et al. DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. Int J Cancer, 2005, 114(I): 74-79.
  • 6Ahrendt SA, Hu Y, Buta M, et al. p53 mutations and survival in stage I non- small-cell lung cancer: results of a prospective study. J Natl Cancer Inst, 2003, 95(13): 961-970.
  • 7Mogi A, Kuwano H. TP53 mutations in nonsmaU cell lung cancer. J Biomed and Biotechnol, 2011: 583929. Epub 2011 Jan 18.
  • 8Lee EB, Jin G, Lee SY, et al. TPS3 mutations in Korean patients with non- small cell lung cancer.J Korean Med Sci, 2010, 25(5): 698-705.
  • 9Suzuki H, Kawagnchi T, Hasegawa T, et al. Prognostic impact of p53 protein overexpression in patients with nodenegative lung adenocarcinoma. Cancer Lett, 2006, 237(2): 242-247.

二级参考文献10

  • 1Bos JL. Ras oncogenes in human cancer:a review. Cancer Res, 1989,49:4682-4689.
  • 2Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst, 2001,93:1062-1074.
  • 3Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. JCO, 2009,27 :2091- 2096.
  • 4Wittwer CT, Reed GH, Gundry CN, et al. High-resolution genotyping 15y amplicon melting analysis using LCGreen. Clin Chem, 2003,49:853-860.
  • 5Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non- small cell lung cancer. BMC Cancer, 2006,6:295.
  • 6Kramer D, Thunnissen FB, Gallegos-Ruiz MI, et al. A fast, sensitive and accurate high resolution melting (HRM) technology- based assay to screen for common K-ras rotations. Cell Oncol, 2009,31 : 161-167.
  • 7Van Cutsem E, Lang I, D' haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab : The CRYSTAL experience. J Clin Oncol,2008,26 : 2.
  • 8Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic coloreetal cancer (mCRC) with FOLFOX with or without cetuximab : The OPUS experience. J Clin Oncol, 2008,26:4000.
  • 9Cutsem EV, Claus-Henning K, Erika H, et al. ECetuximab and Chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 2009,360 : 1408-1417.
  • 10Jolien T, Miriam K, Annemieke C, et al. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic. N Engl J Med, 2009,360 : 563 -572.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部